Astex – Oncology and CNS Drug Discovery & Development

Committed to the fight against cancer and CNS disorders

Committed to the fight against cancer and CNS disorders

World leading innovative drug discovery & development

Our research and development teams utilize our cutting edge technology platform in the relentless pursuit of innovative solutions that address the extensive and complex challenges in oncology and diseases of the CNS.

Astex has built a rich product portfolio with multiple drugs in clinical development

Latest from Astex

23 September 2021

Astex Pharmaceuticals Presents Overall Survival Data From ASCERTAIN Phase 3 Study of Oral Hypomethylating Agent INQOVI® (decitabine and cedazuridine) in MDS and CMML at International Congress on Myelodysplastic Syndromes

In the News

13 January 2021
Taiho and Astex Extend Strategic Oncology Collaboration with MSD Granting Exclusive License to SHP2 Program

12 January 2021
David Rees, Chief Scientific Officer, inducted to the Royal Society of Chemistry BMCS (Biological and Medicinal Chemistry Sector) Hall of Fame.

Sustaining Innovation

Innovative postdoctoral research fellowships

Career Opportunities

We seek to attract and retain talented individuals who are passionate about improving patient outcomes.

icon_Interactive_White

Interactive Scientific Resources

Explore 3D protein-ligand structures from recent Astex publications.

Download software developed by Astex scientists.